索拉非尼防治肝癌微血管侵犯的研究进展

详细信息    查看全文 | 推荐本文 |

英文篇名：Recent progress of sorafenib in adjuvant treatment of hepatocellular carcinoma with microvascular invasion 作者：毕新宇 英文作者：BI Xin-yu;Department of Hepatobiliary Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; 关键词：肝细胞肝癌 ; 微血管侵犯 ; 索拉非尼 ; 辅助治疗 英文关键词：Hepatocellular Carcinoma;;Microvascular invasion;;Sorafenib;;Adjuvant treatment 中文刊名：GADZ 英文刊名：Electronic Journal of Liver Tumor 机构：国家癌症中心/国家肿瘤临床医学研究中心/,中国医学科学院北京协和医学院肿瘤医院肝胆外科; 出版日期：2019-03-30 出版单位：肝癌电子杂志 年：2019 期：v.6 基金：中国传染病国家重点项目,项目编号:2017ZX10201021-007-003 语种：中文; 页：GADZ201901001 页数：3 CN：01 ISSN：11-9351/R 分类号：9-11

摘要

微血管侵犯是肝细胞肝癌患者预后不良的危险因素,通常依靠术后病理检测明确。目前对于伴有微血管侵犯的肝细胞肝癌患者其术后辅助治疗方面缺乏充分的临床证据。索拉非尼是一种多激酶抑制剂,主要用于用于无法手术或伴有远处转移的晚期肝细胞肝癌患者。本文将对索拉非尼用于伴有微血管侵犯的肝细胞肝癌患者的术后辅助治疗方面的研究进展进行简要介绍。
        Microvascular invasion is a risk factor for poor prognosis in patients with hepatocellular carcinoma,and is usually determined by postoperative pathological examination.There is currently insufficient clinical evidence for postoperative adjuvant therapy in hepatocellular carcinoma patients with microvascular invasion.Sorafenib is a multi-kinase inhibitor used primarily in patients with advanced hepatocellular carcinoma who are inoperable or have distant metastases.This article will briefly introduce the research progress of sorafenib for postoperative adjuvant therapy in patients with hepatocellular carcinoma with microvascular invasion.

引文

[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
    [2]中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华肝脏病杂志,2017,25(12):886-895.
    [3]Rndriguez-Perrlvarez M,Luong TV,Andreana L,et al.Asystematic review of microvascular invasion in hepatocellularcarcinoma:diagnostic and prognostic variability[J].Ann SurgOncol,2013,20(1):325-339.
    [4]蒋亚波,郭卫星,程树群.肝细胞癌伴门静脉癌栓发生机制的研究进展[J].中国细胞生物学学报,2017,39(2):1-6.
    [5]Xue J,Xie VK,Wang P,et al.Interrelationships of circulating tumor cells with metastasis and thrombosis:role of microRNAs[J].Curr Pharm Des.2014,20(33):5298-5308.
    [6]Yoshida T,Hisamoto T,AkibaJ,et al.Spreds,inhibitorsoftheRas/ERK signal transduction,aredysregulated in human he-Dat0cellularcarcinoma and linked to themalignantphenotypeoftumors[J].Oncogene,2006,25(45):6056-6066.
    [7]Wang SN,Chuang SC,Lee KT.Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery:A pilot study[J].Hepatol Res,2014,44(5):523-531.
    [8]Huang Y,Ze-Yu Z,Yu-Fan Z,et al.Survival analysis of sorafenib in hepatocellular carcinoma patients with microvascular invasion after hepatectomy.ESMO.2018 Abstract#1926P.
    [9]XinyuBi,JieGao,XuhuiHu,et al.Sorafenib versus transarterial chemoembolization as adjuvant therapies for patients with hepatocellular carcinoma and microvascular invasion.[R/OL].ASCO-GI 2019,Abstract 244.
    [10]Chen J,Lin-Ye H,Xiao-Yun Z,et al.Postoperative adjuvant sorafenib for hepatocellular carcinoma patients with vascular invasion:a propensity score matching analysis.SSO.2019.